Replay available

Imunon, Inc. (IMNN) Q3 2025 Earnings Call

Imunon, Inc. (NASDAQ: IMNN) Q3 2025 earnings conference call, held 2025-11-13. Replay captured from the company's public earnings webcast.

Thu, November 13, 2025 at 11:00 AMendedReplay
Imunon, Inc. (IMNN) Q3 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Dr. Khurshid Anwar

Chief Scientific Officer, Immunon

Dr. Douglas Fowler

Chief Medical Officer, Immunon

James Molloy

Analyst, Alliance Global Partners

Peter Wozo

Healthcare Investor Relations Representative, ICR for Immunon

David Bolt

Analyst, Zax

Emily Bodnar

Analyst, HC Wainwright

Kim Graper

Interim Chief Financial Officer, Immunon

Dr. Stacey Lindborg

President & Chief Executive Officer, Immunon

Replay transcript excerpt

Good morning. My name is Myron Fernandes and I will be your operator today. At this time, I would like to welcome you all to Imminent Thirds Quarter Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. Following the speaker's prepared remarks, there will be a question and answer session. You may press star and 1 on your phone to ask a question at that time. Please keep in mind, if you are using a speakerphone, you must release your mute function to allow the signal to reach our equipment. Again, that's star and one to ask a question during the Q&A session. I would now like to turn the call over to Peter Wozo from ICR Healthcare Investor Relations Representative for Immune. Please go ahead. Thank you, Myron. Good morning, everyone, and welcome to Immunize Third Quarter 2025 Financial Results and Business Update Conference Call. During today's call, management will be making forward-looking statements regarding Immunize expectations and projections about future events. In general, forward-looking statements can be identified by the words such as expects, anticipates, believes, or other similar expressions. These statements are based on current expectations and are subject to a number of risks and uncertainties, including those set forth in the company's periodic filings with the Securities and Exchange Commission. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. I also caution that the content of this conference call is accurate only as of the date of this live broadcast, November 13th, 2025. Immunon undertakes no obligation to revise or update comments made during this call, except by required by law. With that said, I would like to turn the call over to Dr...

More from Imunon, Inc.